Belantamab Mafodotin Combination Therapy
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Arms / Cohorts
Experimental:Phase 1: Iberdomide, Belantamab Mafodotin, Dexamethasone
Not yet accepting
Active Comparator:Phase 2, Arm 1: Belantamab Mafodotin, Dexamethasone
Not yet accepting
Experimental:Phase 2, Arm 2: Iberdomide, Belantamab Mafodotin, Dexamethasone
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.